ELI LILLY AND COMPANY Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation
ELI LILLY AND COMPANY (LLY) reported Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation of $49.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation · last filed 2025-02-19
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2024 was $49.70M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2022 was $52.60M, a 20.54% decline from fiscal 2021.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2021 was $66.20M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2019 was $16.20M, a 161.29% increase from fiscal 2018.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation 12 month | Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation 12 month as first filed |
|---|---|---|
| 2024-12-31 | $49.70M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $52.60M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $66.20M 10-K · filed 2024-02-21 | |
| 2019-12-31 | $16.20M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $6.20M 10-K · filed 2021-02-17 | $6.80M 10-K · filed 2019-02-19 |
| 2016-12-31 | $4.30M 8-K · filed 2019-10-24 | |
| 2015-12-31 | $24.70M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $16.80M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $3.90M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |